{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:37:52Z","timestamp":1761863872406},"reference-count":0,"publisher":"Georg Thieme Verlag KG","issue":"03","funder":[{"name":"Novo Nordisk Pharma GmbH"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2020,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>\n                        Purpose To assess quality of life, glycemic control, and\n                        safety\/tolerability associated with liraglutide versus insulin\n                        initiation in patients with type 2 diabetes in Germany.<\/jats:p><jats:p>\n                        Methods Liraglutide\/insulin-na\u00efve adults with type 2\n                        diabetes and inadequate glycemic control despite using oral antidiabetic\n                        medication were assigned to liraglutide (\u22641.8\u2009mg daily;\n                        n=878) or any insulin (n=382) according to the treating\n                        physician\u2019s decision and followed for 52 weeks. The primary\n                        objective was to evaluate Audit of Diabetes-Dependent Quality of Life\n                        (ADDQoL) scores.<\/jats:p><jats:p>\n                        Results At baseline, the liraglutide group was younger and had\n                        shorter type 2 diabetes duration, lower glycated hemoglobin\n                            (HbA1c), higher body mass index, and a lower prevalence of\n                        certain diabetes-related complications than the insulin group (all\n                        p&lt;0.05). ADDQoL average weighted impact scores improved numerically\n                        in both groups from baseline to 52 weeks (mean difference [95%\n                        confidence interval], liraglutide vs. insulin: 0.159 [\u22120.023;0.340];\n                        not significant). Changes in general wellbeing and five ADDQoL domains\n                        significantly favored liraglutide (remaining 14 domains, not significant).\n                            HbA1c reductions were greater with insulin than liraglutide\n                        (\u22122.0% vs. \u22121.2%; p&lt;0.01); however,\n                        mean HbA1c after 52 weeks was 7.2% in both groups.\n                        Compared with insulin, liraglutide significantly decreased body mass index\n                            (\u22121.54\u2009kg\/m2 vs.\n                            +0.27\u2009kg\/m2; p&lt;0.001),\n                        systolic blood pressure (\u22125.03\u2009mmHg vs.\n                        \u22121.03\u2009mmHg; p&lt;0.01) and non-severe hypoglycemia\n                        (0.85% vs. 4.55% at 52 weeks; p&lt;0.01). Adverse drug\n                        reactions were reported for&lt;3% of patients in both\n                        groups.<\/jats:p><jats:p>\n                        Conclusions Liraglutide improved certain ADDQoL components and\n                        reduced body mass index, systolic blood pressure, and non-severe\n                        hypoglycemia versus insulin. Both treatments improved glycemic control.<\/jats:p>","DOI":"10.1055\/a-0636-3961","type":"journal-article","created":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T23:23:29Z","timestamp":1535585009000},"page":"170-181","source":"Crossref","is-referenced-by-count":5,"title":["Quality of Life, Glycemic Control, Safety and Tolerability Associated\n                    with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in\n                    Germany: Results from the Prospective, Non-interventional LIBERTY\n                    Study"],"prefix":"10.1055","volume":"128","author":[{"given":"Rainer","family":"Lundershausen","sequence":"additional","affiliation":[{"name":"Diabetes Centre Erfurt\/Bad Berka, Erfurt, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabrina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik\n                    (IPAM), Wismar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Hashim","sequence":"additional","affiliation":[{"name":"Ingress Health, AC Rotterdam, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Kienh\u00f6fer","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma GmbH, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kipper","sequence":"additional","affiliation":[{"name":"Novo Nordisk Pharma GmbH, Mainz, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Wilke","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Pharmako\u00f6konomie und Arzneimittellogistik\n                    (IPAM), Wismar, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2018,8,29]]},"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-0636-3961.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T23:50:38Z","timestamp":1583365838000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-0636-3961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,29]]},"references-count":0,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,3,4]]},"published-print":{"date-parts":[[2020,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-0636-3961","relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,29]]}}}